Posted by Michael Wonder on 14 Dec 2024
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for Pluvicto
13 December 2024 - Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA positive metastatic castration resistant prostate cancer.
Novartis Pharmaceuticals Canada is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Pluvicto (lutetium (177Lu) vipivotide tetraxetan injection).
